The Clinical Investigations Support Office (CISO) serves as a centralized unit to oversee the clinical research infrastructure and assist investigators in their conduct of clinical trials and translational research projects. CISO has been reorganized following recommendations of an external advisory group and the Cancer Center Executive Committee and with the concurrence of the NCCC External Advisory Committee. The 58 personnel are now located in 15 of newly remodeled contiguous offices in the Ezralow Tower of the Cancer Center. CISO has three main operational units: 1) Protocol Administration;2) Protocol Implementation;and 3) Administrative/Business Management. The Protocol Administration Unit provides the centralized consultation and regulatory services necessary for the design, initiation, and conduct of externally-funded and internally peer-reviewed and monitored clinical trials. The Protocol Implementation Unit provides the centralized function of advising and assisting investigators in patient eligibility assessments, patient recruitment, data quality control and oversight. The Administrative/Business Management Unit was recently created in 2007 in order to coordinate CISO's relationships with institutional entities outside the Cancer Center and with sponsors. It is also charged with assisting the various investigators and sections to manage their funding sources, allocate their financial and human resources in an efficient manner, and be able to make sound projections for future growth. In addition to the services provided by the three operational units, CISO plays a central coordinating role within the Cancer Center through its interactions with other cores such as the Biostatistics Core, the Cancer Research Informatics Core (CRIC), the Translational Pathology Core, and the Protocol Review and Monitoring System entities (Clinical Investigations Committee and the Quality Assurance and Monitoring Committee). The Cancer Center Executive Committee exercises full authority over CISO policies and resource allocation and reviews the CISO's performance on a biannual basis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-39
Application #
8589359
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
39
Fiscal Year
2014
Total Cost
$392,416
Indirect Cost
$142,794
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Liu, Minmin; Zhang, Lian; Li, Hongtao et al. (2018) Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma. Hepatology 68:1412-1428
Miller, Kimberly A; Ramirez, Cynthia N; Wojcik, Katherine Y et al. (2018) Prevalence and correlates of health information-seeking among Hispanic and non-Hispanic childhood cancer survivors. Support Care Cancer 26:1305-1313
Belic, Jelena; Graf, Ricarda; Bauernhofer, Thomas et al. (2018) Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. Int J Cancer 143:1236-1248
Tobin, Jessica; Allem, Jon-Patrick; Slaughter, Rhona et al. (2018) Posttraumatic growth among childhood cancer survivors: Associations with ethnicity, acculturation, and religious service attendance. J Psychosoc Oncol 36:175-188
Schaal, Justin B; Maretzky, Thorsten; Tran, Dat Q et al. (2018) Macrocyclic ?-defensins suppress tumor necrosis factor-? (TNF-?) shedding by inhibition of TNF-?-converting enzyme. J Biol Chem 293:2725-2734
Iriondo, Oihana; Liu, Yarong; Lee, Grace et al. (2018) TAK1 mediates microenvironment-triggered autocrine signals and promotes triple-negative breast cancer lung metastasis. Nat Commun 9:1994
Robison, Nathan J; Yeo, Kee Kiat; Berliner, Adrian P et al. (2018) Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors. J Neurooncol 138:199-207
Naseem, Madiha; Barzi, Afsaneh; Brezden-Masley, Christine et al. (2018) Outlooks on Epstein-Barr virus associated gastric cancer. Cancer Treat Rev 66:15-22
Sebio, A; Stintzing, S; Heinemann, V et al. (2018) A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials. Pharmacogenomics J 18:43-48
Peres, Lauren C; Risch, Harvey; Terry, Kathryn L et al. (2018) Racial/ethnic differences in the epidemiology of ovarian cancer: a pooled analysis of 12 case-control studies. Int J Epidemiol 47:460-472

Showing the most recent 10 out of 842 publications